Chen X, et al. (2022) Identification of HPCAL1 as a specific autophagy receptor involved in ferroptosis. Autophagy, 1-21 35403545

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T149-p - HPCAL1 (human) ▲

Modsite: EStPEKRtDKIFRQM SwissProt Entrez-Gene Orthologous residues HPCAL1 (human): T149‑p, HPCAL1 (mouse): T149‑p, HPCAL1 (rat): T149‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  fibrosarcoma of soft tissue Relevant cell lines - cell types - tissues:  HT1080 (fibroblast) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE PKCT (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, phospho-antibody, co-immunoprecipitation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes RSL3 increase HBSS no change compared to control rapamycin no change compared to control Erastin increase Go_6983 RSL3 inhibit treatment-induced increase Go_6983 Erastin inhibit treatment-induced increase GF109203X Erastin inhibit treatment-induced increase GF109203X RSL3 inhibit treatment-induced increase HPCAL1 inhibitor RSL3 inhibit treatment-induced increase siRNA decrease PKCT siRNA Downstream Regulation Effect of modification (process):  autophagy, induced, carcinogenesis, inhibited, cell growth, inhibited

T638-p - PKCA (human) ▲

Modsite: TRGQPVLtPPDQLVI SwissProt Entrez-Gene Orthologous residues PKCA (human): T638‑p, PKCA (mouse): T638‑p, PKCA (rat): T638‑p, PKCA (cow): T638‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  fibrosarcoma of soft tissue Relevant cell lines - cell types - tissues:  Calu-1 (squamous), HT1080 (fibroblast) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes RSL3 no change compared to control

T642-p - PKCB (human) ▲

Modsite: TRQPVELtPtDKLFI SwissProt Entrez-Gene Orthologous residues PKCB (human): T642‑p, PKCB iso2 (human): ‑, PKCB (mouse): T642‑p, PKCB iso2 (mouse): ‑, PKCB (rat): T642‑p, PKCB iso2 (rat): ‑, PKCB (cow): ‑ Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  fibrosarcoma of soft tissue Relevant cell lines - cell types - tissues:  Calu-1 (squamous), HT1080 (fibroblast) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes RSL3 no change compared to control

S661-p - PKCB (human) ▲

Modsite: QNEFAGFsYTNPEFV SwissProt Entrez-Gene Orthologous residues PKCB (human): S661‑p, PKCB iso2 (human): ‑, PKCB (mouse): S661‑p, PKCB iso2 (mouse): ‑, PKCB (rat): S661‑p, PKCB iso2 (rat): ‑, PKCB (cow): ‑ Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  fibrosarcoma of soft tissue Relevant cell lines - cell types - tissues:  Calu-1 (squamous), HT1080 (fibroblast) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes RSL3 no change compared to control

T507-p - PKCD (human) ▲

Modsite: FGEsRAstFCGtPDy SwissProt Entrez-Gene Orthologous residues PKCD (human): T507‑p, PKCD iso2 (human): T538‑p, PKCD (mouse): T505‑p, PKCD iso2 (mouse): T531‑p, PKCD (rat): T505‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  fibrosarcoma of soft tissue Relevant cell lines - cell types - tissues:  Calu-1 (squamous), HT1080 (fibroblast) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes RSL3 no change compared to control

S645-p - PKCD (human) ▲

Modsite: LNEkARLsysDKNLI SwissProt Entrez-Gene Orthologous residues PKCD (human): S645‑p, PKCD iso2 (human): S676‑p, PKCD (mouse): S643‑p, PKCD iso2 (mouse): S669‑p, PKCD (rat): S643‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  fibrosarcoma of soft tissue Relevant cell lines - cell types - tissues:  Calu-1 (squamous), HT1080 (fibroblast) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes RSL3 no change compared to control

T538-p - PKCT (human) ▲

Modsite: LGDAktNtFCGtPDy SwissProt Entrez-Gene Orthologous residues PKCT (human): T538‑p, PKCT (mouse): T538‑p, PKCT (rat): T538‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  fibrosarcoma of soft tissue Relevant cell lines - cell types - tissues:  Calu-1 (squamous), HT1080 (fibroblast) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes RSL3 increase HBSS no change compared to control rapamycin no change compared to control HPCAL1 inhibitor RSL3 no effect upon treatment-induced increase Downstream Regulation Effect of modification (function):  enzymatic activity, induced Effect of modification (process):  autophagy, induced, carcinogenesis, inhibited, cell growth, inhibited

S676-p - PKCT (human) ▲

Modsite: LNEkPRLsFADRALI SwissProt Entrez-Gene Orthologous residues PKCT (human): S676‑p, PKCT (mouse): S676‑p, PKCT (rat): S676‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  fibrosarcoma of soft tissue Relevant cell lines - cell types - tissues:  Calu-1 (squamous), HT1080 (fibroblast) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes RSL3 no change compared to control

T410-p - PKCZ (human) ▲

Modsite: GPGDtTstFCGtPNy SwissProt Entrez-Gene Orthologous residues PKCZ (human): T410‑p, PKCZ iso2 (human): T227‑p, PKCZ iso3 (human): T306‑p, PKCZ (mouse): T410‑p, PKCZ (rat): T410‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  fibrosarcoma of soft tissue Relevant cell lines - cell types - tissues:  Calu-1 (squamous), HT1080 (fibroblast) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes RSL3 no change compared to control

S738-p - PRKD1 (human) ▲

Modsite: ARIIGEksFRRsVVG SwissProt Entrez-Gene Orthologous residues PRKD1 (human): S738‑p, PRKD1 (mouse): S744‑p, PRKD1 (rat): S744‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  fibrosarcoma of soft tissue Relevant cell lines - cell types - tissues:  Calu-1 (squamous), HT1080 (fibroblast) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes RSL3 no change compared to control

S742-p - PRKD1 (human) ▲

Modsite: GEksFRRsVVGtPAy SwissProt Entrez-Gene Orthologous residues PRKD1 (human): S742‑p, PRKD1 (mouse): S748‑p, PRKD1 (rat): S748‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  fibrosarcoma of soft tissue Relevant cell lines - cell types - tissues:  Calu-1 (squamous), HT1080 (fibroblast) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes RSL3 no change compared to control